Top

Current Treatment Options in Gastroenterology

Published in:

01-09-2017 | Pancreas (V Chandrasekhara, Section Editor)

Endoscopic Palliation of Pancreatic Cancer

Authors: Vishal B. Gohil, MD, Jason B. Klapman, MD, FASGE

Published in: Current Treatment Options in Gastroenterology | Issue 3/2017

Opinion statement

Pancreas cancer is a fourth-leading cause of cancer death in the USA and its incidence is rising as the population is aging. The majority of patients present at an advanced stage due to the silent nature of the disease and treatment have focused more on palliation than curative intent. Gastroenterologists have become integral in the multidisciplinary care of these patients with a focus on providing endoscopic palliation of pancreas cancer. The three most common areas that gastroenterologists palliate endoscopically are biliary obstruction, cancer-related pain, and gastric outlet obstruction. To palliate biliary obstruction, the procedure of choice is to perform endoscopic retrograde cholangiopancreatography (ERCP) with biliary stent placement. We tend to place covered self-expandable metal stents (SEMS) due to their longer patency and removability unless the patient has resectable disease. Pancreas cancer pain is a result of tumor infiltration of the celiac plexus and can be severe and poorly responsive to narcotics. To improve pain control, neurolysis of the celiac plexus has been performed for decades. Since 1996, neurolysis of the celiac area has been performed endoscopically by Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis. This has proven to be as safe and effective as traditional non-endoscopic methods and has allowed the patients to decrease their narcotic use and improve their pain control. This should be done early on in the course of the disease to have maximal effect. Gastric outlet obstruction (GOO) occurs in approximately 15–20% of patients with pancreas cancer. Endoscopic palliation of GOO can be performed by placing uncovered metal enteral stents across the obstruction. This procedure has proven to be very effective in patients who have a short life expectancy (less than two to 6 months) while surgical bypass should be considered for patients with longer life expectancies because it offers better long-term symptom relief. This chapter will review the current literature, latest advancements, and optimal techniques for endoscopic palliation of pancreatic cancer.

American Cancer Society: Cancer facts and figures 2017. Atlanta, Ga. American Cancer Society. 2017.

Barkin JS, Goldstein JA. Diagnostic approach to pancreatic cancer. Gastroenterol Clin N Am. 1999;28(3):709–22. xiCrossRef

Kozarek RA. Endoscopy in the management of malignant obstructive jaundice. Gastrointest Endosc Clin N Am. 1996;6(1):153–76.PubMed

Levy MJ, Baron TH, Gostout CJ, Petersen BT, Farnell MB. Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: an evidence-based approach. Clin Gastroenterol Hepatol. 2004;2(4):273–85.PubMedCrossRef

Moss AC, Morris E, Leyden J, MacMathuna P. Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev. 2007;33(2):213–21. doi:10.1016/j.ctrv.2006.10.006.PubMedCrossRef

Ferreira LE, Baron TH. Endoscopic stenting for palliation of malignant biliary obstruction. Expert Rev Med Devices. 2010;7(5):681–91. doi:10.1586/erd.10.36.PubMedCrossRef

Pfau PR, Pleskow DK, Banerjee S, Barth BA, Bhat YM, Desilets DJ, et al. Pancreatic and biliary stents. Gastrointest Endosc. 2013;77(3):319–27. doi:10.1016/j.gie.2012.09.026.PubMedCrossRef

Cipolletta L, Rotondano G, Marmo R, Bianco MA. Endoscopic palliation of malignant obstructive jaundice: an evidence-based review. Dig Liver Dis. 2007;39(4):375–88. doi:10.1016/j.dld.2006.12.016.PubMedCrossRef

Loew BJ, Howell DA, Sanders MK, Desilets DJ, Kortan PP, May GR, et al. Comparative performance of uncoated, self-expanding metal biliary stents of different designs in 2 diameters: final results of an international multicenter, randomized, controlled trial. Gastrointest Endosc. 2009;70(3):445–53. doi:10.1016/j.gie.2008.11.018.PubMedCrossRef

10.

Dumonceau JM, Tringali A, Blero D, Deviere J, Laugiers R, Heresbach D, et al. Biliary stenting: indications, choice of stents and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy. 2012;44(3):277–98. doi:10.1055/s-0031-1291633.PubMedCrossRef

11.

Moy BT, Birk JW. An update to hepatobiliary stents. J Clin Transl Hepatol. 2015;3(1):67–77. doi:10.14218/jcth.2015.00040.PubMedPubMedCentralCrossRef

12.

Sejpal D. Advancements in biliary stenting. J Clin Gastroenterol. 2012;46(3):191–6. doi:10.1097/MCG.0b013e3182410367.PubMedCrossRef

13.

Yoon WJ, Ryu JK, Yang KY, Paik WH, Lee JK, Woo SM, et al. A comparison of metal and plastic stents for the relief of jaundice in unresectable malignant biliary obstruction in Korea: an emphasis on cost-effectiveness in a country with a low ERCP cost. Gastrointest Endosc. 2009;70(2):284–9. doi:10.1016/j.gie.2008.12.241.PubMedCrossRef

14.

Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet. 1992;340(8834–8835):1488–92.CrossRefPubMed

15.

Kaassis M, Boyer J, Dumas R, Ponchon T, Coumaros D, Delcenserie R, et al. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc. 2003;57(2):178–82. doi:10.1067/mge.2003.66.PubMedCrossRef

16.

Soderlund C, Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc. 2006;63(7):986–95. doi:10.1016/j.gie.2005.11.052.PubMedCrossRef

17.

Speer AG, Cotton PB, MacRae KD. Endoscopic management of malignant biliary obstruction: stents of 10 French gauge are preferable to stents of 8 French gauge. Gastrointest Endosc. 1988;34(5):412–7.PubMedCrossRef

18.

Kadakia SC, Starnes E. Comparison of 10 French gauge stent with 11.5 French gauge stent in patients with biliary tract diseases. Gastrointest Endosc. 1992;38(4):454–9.PubMedCrossRef

19.

Kullman E, Frozanpor F, Soderlund C, Linder S, Sandstrom P, Lindhoff-Larsson A, et al. Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study. Gastrointest Endosc. 2010;72(5):915–23. doi:10.1016/j.gie.2010.07.036.PubMedCrossRef

20.

Kitano M, Yamashita Y, Tanaka K, Konishi H, Yazumi S, Nakai Y, et al. Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial. Am J Gastroenterol. 2013;108(11):1713–22. doi:10.1038/ajg.2013.305.PubMedCrossRef

21.

Telford JJ, Carr-Locke DL, Baron TH, Poneros JM, Bounds BC, Kelsey PB, et al. A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction. Gastrointest Endosc. 2010;72(5):907–14. doi:10.1016/j.gie.2010.08.021.PubMedCrossRef

22.

Saleem A, Leggett CL, Murad MH, Baron TH. Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc. 2011;74(2):321–7.e1-3. doi:10.1016/j.gie.2011.03.1249.PubMedCrossRef

23.

Almadi MA, Barkun AN, Martel M. No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(1):27–37.e1. doi:10.1016/j.cgh.2012.10.019.PubMedCrossRef

24.

Moss AC, Morris E, Leyden J, MacMathuna P. Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol. 2007;19(12):1119–24. doi:10.1097/MEG.0b013e3282f16206.PubMedCrossRef

25.

Committee ASoP, Chandrasekhara V, Khashab MA, Muthusamy VR, Acosta RD, Agrawal D, et al. Adverse events associated with ERCP. Gastrointest Endosc. 2017;85(1):32–47. doi:10.1016/j.gie.2016.06.051.CrossRef

26.

Yang KY, Ryu JK, Seo JK, Woo SM, Park JK, Kim YT, et al. A comparison of the Niti-D biliary uncovered stent and the uncovered Wallstent in malignant biliary obstruction. Gastrointest Endosc. 2009;70(1):45–51. doi:10.1016/j.gie.2008.10.029.PubMedCrossRef

27.

Fumex F, Coumaros D, Napoleon B, Barthet M, Laugier R, Yzet T, et al. Similar performance but higher cholecystitis rate with covered biliary stents: results from a prospective multicenter evaluation. Endoscopy. 2006;38(8):787–92. doi:10.1055/s-2006-944515.PubMedCrossRef

28.

• Nakai Y, Isayama H, Kawakubo K, Kogure H, Hamada T, Togawa O, et al. Metallic stent with high axial force as a risk factor for cholecystitis in distal malignant biliary obstruction. J Gastroenterol Hepatol. 2014;29(7):1557–62. doi:10.1111/jgh.12582. Keep in mind risk factor of developing acute cholecystitis while placing SEMS- neoplastic involvement of cystic duct and SEMS with high axial force.PubMedCrossRef

29.

Artifon EL, Sakai P, Ishioka S, Marques SB, Lino AS, Cunha JE, et al. Endoscopic sphincterotomy before deployment of covered metal stent is associated with greater complication rate: a prospective randomized control trial. J Clin Gastroenterol. 2008;42(7):815–9. doi:10.1097/MCG.0b013e31803dcd8a.PubMedCrossRef

30.

Banerjee N, Hilden K, Baron TH, Adler DG. Endoscopic biliary sphincterotomy is not required for transpapillary SEMS placement for biliary obstruction. Dig Dis Sci. 2011;56(2):591–5. doi:10.1007/s10620-010-1317-z.PubMedCrossRef

31.

Cote GA, Kumar N, Ansstas M, Edmundowicz SA, Jonnalagadda S, Mullady DK, et al. Risk of post-ERCP pancreatitis with placement of self-expandable metallic stents. Gastrointest Endosc. 2010;72(4):748–54. doi:10.1016/j.gie.2010.05.023.PubMedCrossRef

32.

Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA. 2004;291(9):1092–9. doi:10.1001/jama.291.9.1092.PubMedCrossRef

33.

NCCN. NCCN guidelines for pancreas adenocarcinoma. 2017.

34.

Wiersema MJ, Wiersema LM. Endosonography-guided celiac plexus neurolysis. Gastrointest Endosc. 1996;44(6):656–62.PubMedCrossRef

35.

Luz LP, Al-Haddad MA, DeWitt JA. EUS-guided celiac plexus interventions in pancreatic cancer pain: an update and controversies for the endosonographer. Endoscopic Ultrasound. 2014;3(4):213–20. doi:10.4103/2303-9027.144515.PubMedPubMedCentralCrossRef

36.

Bang JY, Hasan MK, Sutton B, Holt BA, Navaneethan U, Hawes R, et al. Intraprocedural increase in heart rate during EUS-guided celiac plexus neurolysis: clinically relevant or just a physiologic change? Gastrointest Endosc. 2016;84(5):773–9.e3. doi:10.1016/j.gie.2016.03.1496.PubMedCrossRef

37.

Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer. Am J Gastroenterol. 2007;102(2):430–8. doi:10.1111/j.1572-0241.2006.00967.x.PubMedCrossRef

38.

Puli SR, Reddy JB, Bechtold ML, Antillon MR, Brugge WR. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: a meta-analysis and systematic review. Dig Dis Sci. 2009;54(11):2330–7. doi:10.1007/s10620-008-0651-x.PubMedCrossRef

39.

Kaufman M, Singh G, Das S, Concha-Parra R, Erber J, Micames C, et al. Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer. J Clin Gastroenterol. 2010;44(2):127–34. doi:10.1097/MCG.0b013e3181bb854d.PubMedCrossRef

40.

Nagels W, Pease N, Bekkering G, Cools F, Dobbels P. Celiac plexus neurolysis for abdominal cancer pain: a systematic review. Pain Med. 2013;14(8):1140–63. doi:10.1111/pme.12176.PubMedCrossRef

41.

Wyse JM, Carone M, Paquin SC, Usatii M, Sahai AV. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(26):3541–6. doi:10.1200/jco.2010.32.2750.CrossRef

42.

Levy MJ, Topazian MD, Wiersema MJ, Clain JE, Rajan E, Wang KK, et al. Initial evaluation of the efficacy and safety of endoscopic ultrasound-guided direct ganglia neurolysis and block. Am J Gastroenterol. 2008;103(1):98–103. doi:10.1111/j.1572-0241.2007.01607.x.PubMedCrossRef

43.

Ascunce G, Ribeiro A, Reis I, Rocha-Lima C, Sleeman D, Merchan J, et al. EUS visualization and direct celiac ganglia neurolysis predicts better pain relief in patients with pancreatic malignancy (with video). Gastrointest Endosc. 2011;73(2):267–74. doi:10.1016/j.gie.2010.10.029.PubMedCrossRef

44.

Doi S, Yasuda I, Kawakami H, Hayashi T, Hisai H, Irisawa A, et al. Endoscopic ultrasound-guided celiac ganglia neurolysis vs. celiac plexus neurolysis: a randomized multicenter trial. Endoscopy. 2013;45(5):362–9. doi:10.1055/s-0032-1326225.PubMedCrossRef

45.

Minaga K, Kitano M, Sakamoto H, Miyata T, Imai H, Yamao K, et al. Predictors of pain response in patients undergoing endoscopic ultrasound-guided neurolysis for abdominal pain caused by pancreatic cancer. Ther Adv Gastroenterol. 2016;9(4):483–94. doi:10.1177/1756283x16644248.CrossRef

46.

• Fujii-Lau LL, Bamlet WR, Eldrige JS, Chari ST, Gleeson FC, Abu Dayyeh BK, et al. Impact of celiac neurolysis on survival in patients with pancreatic cancer. Gastrointest Endosc. 2015;82(1):46–56 e2. doi:10.1016/j.gie.2014.12.036. Retrospective study suggests that EUS-CPN is an independent predictor of shortened survival in pancreas cancer patients.PubMedCrossRef

47.

Sahai AV, Lemelin V, Lam E, Paquin SC. Central vs. bilateral endoscopic ultrasound-guided celiac plexus block or neurolysis: a comparative study of short-term effectiveness. Am J Gastroenterol. 2009;104(2):326–9. doi:10.1038/ajg.2008.64.PubMedCrossRef

48.

LeBlanc JK, Al-Haddad M, McHenry L, Sherman S, Juan M, McGreevy K, et al. A prospective, randomized study of EUS-guided celiac plexus neurolysis for pancreatic cancer: one injection or two? Gastrointest Endosc. 2011;74(6):1300–7. doi:10.1016/j.gie.2011.07.073.PubMedCrossRef

49.

O'Toole TM, Schmulewitz N. Complication rates of EUS-guided celiac plexus blockade and neurolysis: results of a large case series. Endoscopy. 2009;41(7):593–7. doi:10.1055/s-0029-1214868.PubMedCrossRef

50.

Alvarez-Sanchez MV, Jenssen C, Faiss S, Napoleon B. Interventional endoscopic ultrasonography: an overview of safety and complications. Surg Endosc. 2014;28(3):712–34. doi:10.1007/s00464-013-3260-5.PubMedCrossRef

51.

Loeve US, Mortensen MB. Lethal necrosis and perforation of the stomach and the aorta after multiple EUS-guided celiac plexus neurolysis procedures in a patient with chronic pancreatitis. Gastrointest Endosc. 2013;77(1):151–2. doi:10.1016/j.gie.2012.03.005.PubMedCrossRef

52.

Jang HY, Cha SW, Lee BH, Jung HE, Choo JW, Cho YJ, et al. Hepatic and splenic infarction and bowel ischemia following endoscopic ultrasound-guided celiac plexus neurolysis. Clin Endosc. 2013;46(3):306–9. doi:10.5946/ce.2013.46.3.306.PubMedPubMedCentralCrossRef

53.

Gimeno-Garcia AZ, Elwassief A, Paquin SC, Sahai AV. Fatal complication after endoscopic ultrasound-guided celiac plexus neurolysis. Endoscopy. 2012;44(Suppl 2 UCTN):E267. doi:10.1055/s-0032-1309709.PubMed

54.

Fujii L, Clain JE, Morris JM, Levy MJ. Anterior spinal cord infarction with permanent paralysis following endoscopic ultrasound celiac plexus neurolysis. Endoscopy. 2012;44(Suppl 2 UCTN):E265–6. doi:10.1055/s-0032-1309708.PubMed

55.

Mittal MK, Rabinstein AA, Wijdicks EF. Pearls & oy-sters: acute spinal cord infarction following endoscopic ultrasound-guided celiac plexus neurolysis. Neurology. 2012;78(9):e57–9. doi:10.1212/WNL.0b013e318248df51.PubMedCrossRef

56.

Minaga K, Kitano M, Imai H, Miyata T, Kudo M. Acute spinal cord infarction after EUS-guided celiac plexus neurolysis. Gastrointest Endosc. 2016;83(5):1039–1040; discussion 40. doi:10.1016/j.gie.2015.10.044.PubMedCrossRef

57.

Mulhall AM, Rashkin MC, Pina EM. Bilateral diaphragmatic paralysis: a rare complication related to endoscopic ultrasound-guided celiac plexus neurolysis. Ann Am Thorac Soc. 2016;13(9):1660–2. doi:10.1513/AnnalsATS.201603-190LE.PubMedCrossRef

58.

Lalueza A, Lopez-Medrano F, del Palacio A, Alhambra A, Alvarez E, Ramos A, et al. Cladosporium macrocarpum brain abscess after endoscopic ultrasound-guided celiac plexus block. Endoscopy. 2011;43(Suppl 2 UCTN):E9–10. doi:10.1055/s-0030-1255804.PubMedCrossRef

59.

Johnson CD. Gastric outlet obstruction malignant until proved otherwise. Am J Gastroenterol. 1995;90(10):1740.PubMed

60.

Shone DN, Nikoomanesh P, Smith-Meek MM, Bender JS. Malignancy is the most common cause of gastric outlet obstruction in the era of H2 blockers. Am J Gastroenterol. 1995;90(10):1769–70.PubMed

61.

Chowdhury A, Dhali GK, Banerjee PK. Etiology of gastric outlet obstruction. Am J Gastroenterol. 1996;91(8):1679.PubMed

62.

Dormann A, Meisner S, Verin N, Wenk LA. Self-expanding metal stents for gastroduodenal malignancies: systematic review of their clinical effectiveness. Endoscopy. 2004;36(6):543–50. doi:10.1055/s-2004-814434.PubMedCrossRef

63.

Fukami N, Anderson MA, Khan K, Harrison ME, Appalaneni V, Ben-Menachem T, et al. The role of endoscopy in gastroduodenal obstruction and gastroparesis. Gastrointest Endosc. 2011;74(1):13–21. doi:10.1016/j.gie.2010.12.003.PubMedCrossRef

64.

van Hooft JE, Dijkgraaf MG, Timmer R, Siersema PD, Fockens P. Independent predictors of survival in patients with incurable malignant gastric outlet obstruction: a multicenter prospective observational study. Scand J Gastroenterol. 2010;45(10):1217–22. doi:10.3109/00365521.2010.487916.PubMedCrossRef

65.

Jeurnink SM, Steyerberg EW, van Hooft JE, van Eijck CH, Schwartz MP, Vleggaar FP, et al. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc. 2010;71(3):490–9. doi:10.1016/j.gie.2009.09.042.PubMedCrossRef

66.

Woo SM, Kim DH, Lee WJ, Park KW, Park SJ, Han SS, et al. Comparison of uncovered and covered stents for the treatment of malignant duodenal obstruction caused by pancreaticobiliary cancer. Surg Endosc. 2013;27(6):2031–9. doi:10.1007/s00464-012-2705-6.PubMedCrossRef

67.

van den Berg MW, Walter D, Vleggaar FP, Siersema PD, Fockens P, van Hooft JE. High proximal migration rate of a partially covered “big cup” duodenal stent in patients with malignant gastric outlet obstruction. Endoscopy. 2014;46(2):158–61. doi:10.1055/s-0033-1359023.PubMed

68.

Jeurnink SM, Repici A, Luigiano C, Pagano N, Kuipers EJ, Siersema PD. Use of a colonoscope for distal duodenal stent placement in patients with malignant obstruction. Surg Endosc. 2009;23(3):562–7. doi:10.1007/s00464-008-9880-5.PubMedCrossRef

69.

Mauro MA, Koehler RE, Baron TH. Advances in gastrointestinal intervention: the treatment of gastroduodenal and colorectal obstructions with metallic stents. Radiology. 2000;215(3):659–69. doi:10.1148/radiology.215.3.r00jn30659.PubMedCrossRef

70.

Kochar R, Shah N. Enteral stents: from esophagus to colon. Gastrointest Endosc. 2013;78(6):913–8. doi:10.1016/j.gie.2013.07.015.PubMedCrossRef

71.

Boskoski I, Tringali A, Familiari P, Mutignani M, Costamagna G. Self-expandable metallic stents for malignant gastric outlet obstruction. Adv Ther. 2010;27(10):691–703. doi:10.1007/s12325-010-0061-2.PubMedCrossRef

72.

Adler DG, Baron TH. Endoscopic palliation of malignant gastric outlet obstruction using self-expanding metal stents: experience in 36 patients. Am J Gastroenterol. 2002;97(1):72–8. doi:10.1111/j.1572-0241.2002.05423.x.PubMedCrossRef

73.

van Hooft JE, Uitdehaag MJ, Bruno MJ, Timmer R, Siersema PD, Dijkgraaf MG, et al. Efficacy and safety of the new WallFlex enteral stent in palliative treatment of malignant gastric outlet obstruction (DUOFLEX study): a prospective multicenter study. Gastrointest Endosc. 2009;69(6):1059–66. doi:10.1016/j.gie.2008.07.026.PubMedCrossRef

74.

Piesman M, Kozarek RA, Brandabur JJ, Pleskow DK, Chuttani R, Eysselein VE, et al. Improved oral intake after palliative duodenal stenting for malignant obstruction: a prospective multicenter clinical trial. Am J Gastroenterol. 2009;104(10):2404–11. doi:10.1038/ajg.2009.409.PubMedCrossRef

75.

Graber I, Dumas R, Filoche B, Boyer J, Coumaros D, Lamouliatte H, et al. The efficacy and safety of duodenal stenting: a prospective multicenter study. Endoscopy. 2007;39(9):784–7. doi:10.1055/s-2007-966594.PubMedCrossRef

76.

Kim JH, Song HY, Shin JH, Choi E, Kim TW, Jung HY, et al. Metallic stent placement in the palliative treatment of malignant gastroduodenal obstructions: prospective evaluation of results and factors influencing outcome in 213 patients. Gastrointest Endosc. 2007;66(2):256–64. doi:10.1016/j.gie.2006.12.017.PubMedCrossRef

77.

Lowe AS, Beckett CG, Jowett S, May J, Stephenson S, Scally A, et al. Self-expandable metal stent placement for the palliation of malignant gastroduodenal obstruction: experience in a large, single. UK Cent Clin Radiol. 2007;62(8):738–44. doi:10.1016/j.crad.2007.01.021.CrossRef

78.

Havemann MC, Adamsen S, Wojdemann M. Malignant gastric outlet obstruction managed by endoscopic stenting: a prospective single-centre study. Scand J Gastroenterol. 2009;44(2):248–51. doi:10.1080/00365520802530820.PubMedCrossRef

79.

Kim CG, Choi IJ, Lee JY, Cho SJ, Park SR, Lee JH, et al. Covered versus uncovered self-expandable metallic stents for palliation of malignant pyloric obstruction in gastric cancer patients: a randomized, prospective study. Gastrointest Endosc. 2010;72(1):25–32. doi:10.1016/j.gie.2010.01.039.PubMedCrossRef

80.

Khashab M, Alawad AS, Shin EJ, Kim K, Bourdel N, Singh VK, et al. Enteral stenting versus gastrojejunostomy for palliation of malignant gastric outlet obstruction. Surg Endosc. 2013;27(6):2068–75. doi:10.1007/s00464-012-2712-7.PubMedCrossRef

81.

Shaw JM, Bornman PC, Krige JE, Stupart DA, Panieri E. Self-expanding metal stents as an alternative to surgical bypass for malignant gastric outlet obstruction. Br J Surg. 2010;97(6):872–6. doi:10.1002/bjs.6968.PubMedCrossRef

82.

• Tringali A, Didden P, Repici A, Spaander M, Bourke MJ, Williams SJ, et al. Endoscopic treatment of malignant gastric and duodenal strictures: a prospective, multicenter study. Gastrointest Endosc. 2014;79(1):66–75. doi:10.1016/j.gie.2013.06.032. The article highlights the impact of enteral stent placement in which the technical success was 99% and stent patency was high at one month but tapers off by 6 months which furthermore confirms the need to stratify who gets stentign vs surgery as primary treatment for GOO based on life expectancy.PubMedCrossRef

83.

•• Nagaraja V, Eslick GD, Cox MR. Endoscopic stenting versus operative gastrojejunostomy for malignant gastric outlet obstruction-a systematic review and meta-analysis of randomized and non-randomized trials. J Gastrointest Oncol. 2014;5(2):92–8. doi:10.3978/j.issn.2078-6891.2014.016. This article highlights that endoscopic stent placement is associated with better short-term outcomes with regards to resuming oral intake, hospital stay, and similar complication rates. Recent systemic review evaluating endoscopic stenting versus operative gastrojejunostomy for GOO. Patient treated with SEMS has shorter time to tolerating oral diet and shorter hospital stay.PubMedPubMedCentral

84.

Jeurnink SM, Steyerberg EW, Hof G, van Eijck CH, Kuipers EJ, Siersema PD. Gastrojejunostomy versus stent placement in patients with malignant gastric outlet obstruction: a comparison in 95 patients. J Surg Oncol. 2007;96(5):389–96. doi:10.1002/jso.20828.PubMedCrossRef

85.

No JH, Kim SW, Lim CH, Kim JS, Cho YK, Park JM, et al. Long-term outcome of palliative therapy for gastric outlet obstruction caused by unresectable gastric cancer in patients with good performance status: endoscopic stenting versus surgery. Gastrointest Endosc. 2013;78(1):55–62. doi:10.1016/j.gie.2013.01.041.PubMedCrossRef

86.

Jeurnink SM, van Eijck CH, Steyerberg EW, Kuipers EJ, Siersema PD. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol. 2007;7:18. doi:10.1186/1471-230x-7-18.PubMedPubMedCentralCrossRef

87.

Roy A, Kim M, Christein J, Varadarajulu S. Stenting versus gastrojejunostomy for management of malignant gastric outlet obstruction: comparison of clinical outcomes and costs. Surg Endosc. 2012;26(11):3114–9. doi:10.1007/s00464-012-2301-9.PubMedPubMedCentralCrossRef

88.

Mendelsohn RB, Gerdes H, Markowitz AJ, DiMaio CJ, Schattner MA. Carcinomatosis is not a contraindication to enteral stenting in selected patients with malignant gastric outlet obstruction. Gastrointest Endosc. 2011;73(6):1135–40. doi:10.1016/j.gie.2011.01.042.PubMedCrossRef

89.

Fukami N, Bults A, El Hajj I, Amateau SK, Wani S, Brauer BC, et al. Sa1601 underwater EMR for colorectal lesions: a prospective study on efficacy and safety. Gastrointest Endosc. 2014;79(5):AB270. doi:10.1016/j.gie.2014.05.219.CrossRef

90.

Park JC, Park JJ, Cheoi K, Chung H, Lee H, Shin SK, et al. Clinical outcomes of secondary stent-in-stent self-expanding metal stent placement for primary stent malfunction in malignant gastric outlet obstruction. Dig Liver Dis. 2012;44(12):999–1005. doi:10.1016/j.dld.2012.06.019.PubMedCrossRef

91.

Mutignani M, Tringali A, Shah SG, Perri V, Familiari P, Iacopini F, et al. Combined endoscopic stent insertion in malignant biliary and duodenal obstruction. Endoscopy. 2007;39(5):440–7. doi:10.1055/s-2007-966327.PubMedCrossRef

92.

Topazian M, Baron TH. Endoscopic fenestration of duodenal stents using argon plasma to facilitate ERCP. Gastrointest Endosc. 2009;69(1):166–9. doi:10.1016/j.gie.2008.08.026.PubMedCrossRef

93.

Kahaleh M, Hernandez AJ, Tokar J, Adams RB, Shami VM, Yeaton P. Interventional EUS-guided cholangiography: evaluation of a technique in evolution. Gastrointest Endosc. 2006;64(1):52–9. doi:10.1016/j.gie.2006.01.063.PubMedCrossRef

94.

Khashab MA, Messallam AA, Penas I, Nakai Y, Modayil RJ, De la Serna C, et al. International multicenter comparative trial of transluminal EUS-guided biliary drainage via hepatogastrostomy vs. choledochoduodenostomy approaches. Endosc Int Open. 2016;4(2):E175–81. doi:10.1055/s-0041-109083.PubMedPubMedCentralCrossRef

95.

•• Khashab MA, Kumbhari V, Grimm IS, Ngamruengphong S, Aguila G, El Zein M, et al. EUS-guided gastroenterostomy: the first U.S. clinical experience (with video). Gastrointest Endosc. 2015;82(5):932–8. doi:10.1016/j.gie.2015.06.017. First US clinic experience for EUS-guided gastroenterostomy as an alternative method for palliation of GOO. This study may be ground breaking if further studies confirm the effectiveness of this endoscopic approach and may potentially replace surgical GJ long term.PubMedCrossRef

96.

Barthet M, Binmoeller KF, Vanbiervliet G, Gonzalez JM, Baron TH, Berdah S. Natural orifice transluminal endoscopic surgery gastroenterostomy with a biflanged lumen-apposing stent: first clinical experience (with videos). Gastrointest Endosc. 2015;81(1):215–8. doi:10.1016/j.gie.2014.09.039.PubMedCrossRef

Title: Endoscopic Palliation of Pancreatic Cancer
Authors: Vishal B. Gohil, MD
Jason B. Klapman, MD, FASGE
Publication date: 01-09-2017
Publisher: Springer US
Published in: Current Treatment Options in Gastroenterology / Issue 3/2017
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-017-0145-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 3/2017

Intractable Constipation in the Elderly

Endoscopic Surveillance in Long-standing Colitis

The Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly

Endoscopic Stents for the Biliary Tree and Pancreas

Dysphagia in the Elderly

Quality Indicators in Colonoscopy

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage